1
|
Bretagnol A, Barrier D, Brunet C, Lefebvre I, Messi L, Narcisse É, Vanacker L. [Diagnosis of encephalic death and donor resuscitation for harvesting purposes]. Soins 2023; 68:25-28. [PMID: 37657866 DOI: 10.1016/j.soin.2023.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/03/2023]
Abstract
Encephalic death is a rare and unique pathophysiological process. Its diagnosis and management in the intensive care unit, which are well codified, determine the possibility and short- and long-term outcome of organ and tissue transplants.
Collapse
Affiliation(s)
- Anne Bretagnol
- Coordination hospitalière des prélèvements d'organes et de tissus, centre hospitalier universitaire d'Orléans, 14 avenue de l'Hôpital, 45067 Orléans, France.
| | - Damien Barrier
- Coordination hospitalière des prélèvements d'organes et de tissus, centre hospitalier universitaire d'Orléans, 14 avenue de l'Hôpital, 45067 Orléans, France
| | - Carine Brunet
- Coordination hospitalière des prélèvements d'organes et de tissus, centre hospitalier universitaire d'Orléans, 14 avenue de l'Hôpital, 45067 Orléans, France
| | - Isabelle Lefebvre
- Coordination hospitalière des prélèvements d'organes et de tissus, centre hospitalier universitaire d'Orléans, 14 avenue de l'Hôpital, 45067 Orléans, France
| | - Lydia Messi
- Coordination hospitalière des prélèvements d'organes et de tissus, centre hospitalier universitaire d'Orléans, 14 avenue de l'Hôpital, 45067 Orléans, France
| | - Éric Narcisse
- Coordination hospitalière des prélèvements d'organes et de tissus, centre hospitalier universitaire d'Orléans, 14 avenue de l'Hôpital, 45067 Orléans, France
| | - Ludivine Vanacker
- Coordination hospitalière des prélèvements d'organes et de tissus, centre hospitalier universitaire d'Orléans, 14 avenue de l'Hôpital, 45067 Orléans, France
| |
Collapse
|
2
|
Decoster L, Kenis C, Schallier D, Vansteenkiste J, Nackaerts K, Vanacker L, Vandewalle N, Flamaing J, Lobelle JP, Milisen K, De Grève J, Wildiers H. Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer. Lung 2017. [PMID: 28634893 DOI: 10.1007/s00408-017-0025-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
PURPOSE Older patients with lung cancer are a heterogeneous population making treatment decisions complex. This study aims to evaluate the value of geriatric assessment (GA) as well as the evolution of functional status (FS) in older patients with lung cancer, and to identify predictors associated with functional decline and overall survival (OS). METHODS At baseline, GA was performed in patients ≥70 years with newly diagnosed lung cancer. FS measured by activities of daily living (ADL) and instrumental activities of daily living (IADL) was reassessed at follow-up to define functional decline and OS was collected. Predictors for functional decline and OS were determined. RESULTS Two hundred and forty-five patients were included in this study. At baseline, GA deficiencies were present in all domains and ADL and IADL were impaired in 51 and 63% of patients, respectively. At follow-up, functional decline in ADL was observed in 23% and in IADL in 45% of patients. In multivariable analysis, radiotherapy was predictive for ADL decline. No other predictors for ADL or IADL decline were identified. Stage and baseline performance status were predictive for OS. CONCLUSIONS Older patients with lung cancer present with multiple deficiencies covering all geriatric domains. During treatment, functional decline is observed in almost half of the patients. None of the specific domains of the GA were predictive for functional decline or survival, probably because of the high impact of the aggressiveness of this tumor type leading to a poor prognosis.
Collapse
Affiliation(s)
- L Decoster
- Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium.
| | - C Kenis
- Department of General Medical Oncology, University Hospitals Leuven, Louvain, Belgium.,Department of Geriatric Medicine, University Hospitals Leuven, Louvain, Belgium
| | - D Schallier
- Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium
| | - J Vansteenkiste
- Department of Respiratory Oncology, University Hospitals Leuven, Louvain, Belgium
| | - K Nackaerts
- Department of Respiratory Oncology, University Hospitals Leuven, Louvain, Belgium
| | - L Vanacker
- Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium
| | - N Vandewalle
- Department of Geriatric Medicine, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - J Flamaing
- Department of Geriatric Medicine, University Hospitals Leuven, Louvain, Belgium.,Department of Clinical and Experimental Medicine, KU Leuven, Louvain, Belgium
| | | | - K Milisen
- Department of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Louvain, Belgium
| | - J De Grève
- Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium
| | - H Wildiers
- Department of General Medical Oncology, University Hospitals Leuven, Louvain, Belgium.,Department of Oncology, KU Leuven, Louvain, Belgium
| |
Collapse
|
3
|
Fontaine C, Cappoen N, Renard V, Vuylsteke P, Van Den Bulck H, Glorieux P, t'Kint de Roodenbeke D, Dopchie C, Decoster L, Vanacker L, De Grève J, Awada A, Wildiers H. Abstract P5-16-06: Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Triple negative breast cancer (TNBC) remains a challenging disease with dismal prognosis. Platinum analogs have not yet shown to improve long term outcome in this setting, but are associated with increased pathological complete response rate (pCR) at the cost of higher toxicity.
Aim: To further increase or maintain the high pCR rate with platinum containing schedules while decreasing toxicity by administering low dose weekly carboplatin instead of high-dose 3 weekly carboplatin as in CALGB 40603.(1)
Patients and methods: We evaluated the tolerability and the impact of the addition of weekly carboplatin (CP) to paclitaxel (P) and dose dense epirubicin-cyclofosfamide (EC) on pCR in an open-label multicenter phase II study in stage II/III TNBC patients (pts). Sixty three pts received dose dense paclitaxel (P:80mg/m2/wk) concurrent with carboplatin (CP: AUC=2) for 12 wks, followed by two-weekly epirubicin (E:90mg/m2) and cyclophosphamide (C:600mg/m2) for 4 cycles. The primary endpoint is pCR in the breast and axilla. Additionally treatment deliveryand adverse events are recorded. A correlative assessment of germline mutations in homologous recombination (HR) genes is planned. Pts are monitored for response by magnetic resonance and mammography and also for relapse free survival and time to treatment failure. The study size sample has been calculated according to the optimal Simon's two-stage design method. The target sample size was 63 patients with 80% power to detect a pCR rate of ≥47% (α= 0.05).
Results: Accrual to the study is completed with 63 eligible pts with operable, noninflammatory stage II and III TNBC included. Most patients were between 40 and 60 yrs old and were clinical stageT2 tumors. Half of the pts were clinically node + and 70% were G3. Sixty six percent had breast conserving surgery. Sixteen out of 26 (61.5%) of the currently evaluable pts achieved a pCR rate in the breast and axilla. The other ongoing patients have not yet reached this endpoint. Four out of 21 evaluable pts that completed the chemotherapy missed two or more doses of CP due to neutropenia(NP) G3/4(2), general deterioration G3(1) and polyneuropathy(PNP) G3(1) and seven pts needed one dose reduction of P and/or CP due to NP G3-4 (3-2) and PNP G2(1) and one abdominal infection.
Conclusion: These preliminary data suggest that the addition of weekly carboplatinum to neoadjuvant paclitaxel and EC is feasible and has a promising pCR rate in the breast and axilla as high as 61.5% in early TNBC pts. More mature toxicity and outcome data and correlation with genome analysis will be presented.
(1) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once per week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603(Alliance) Sikov WM et al. J Clin Oncol 33:13-21; 2014.
Citation Format: Fontaine C, Cappoen N, Renard V, Vuylsteke P, Van Den Bulck H, Glorieux P, t'Kint de Roodenbeke D, Dopchie C, Decoster L, Vanacker L, De Grève J, Awada A, Wildiers H. Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-06.
Collapse
Affiliation(s)
- C Fontaine
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - N Cappoen
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - V Renard
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - P Vuylsteke
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - H Van Den Bulck
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - P Glorieux
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - D t'Kint de Roodenbeke
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - C Dopchie
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - L Decoster
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - L Vanacker
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - J De Grève
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - A Awada
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| | - H Wildiers
- UZ Brussel, Jette, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Belgian Society of Medical Oncology (BSMO), Jette, Brussels, Belgium; Jules Bordet Institute, Brussels, Belgium
| |
Collapse
|
4
|
Shahi RB, Caljon B, De Brakeleer S, Decoster L, Fontaine C, Vanacker L, Vanhoeij M, Pauwels I, Bonduelle M, Vandooren S, Croes D, Teugels E, De Greve J. Abstract PD7-04: Exome based germline mutation detection in a panel of 372 cancer associated genes in BRCA1/2-negative familial breast cancer patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-pd7-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Ten to 20% percent of all breast cancers occur in a familial context and in 20-30% of these cases a mutation in the BRCA1 or BRCA2, CHEK2 genes or, more rarely, in PALB2 can be found. The remaining cases remain routinely undiagnosed with regard to a possible genetic cause.
We have examined a cohort of undiagnosed probands using exome germline sequencing in order to identify other potential breast cancer predisposition genes.
Methods:
In total, 63 BRCA1/2-negative high risk familial BC cases (BRCAX) were considered for pair-end whole exome germline DNA sequencing on a HiSeq1500 (Illumina). High quality reads were mapped (BWA-MEM) to the reference genome (hg19) and variants were called according to GATK best practice guideline. The variants detected within the panel of 372 cancer associated genes were annoted with ANNOVAR. Synonymous variant as well as variants with MAF>1% were discarded. In a first phase protein truncating variants were validated using another NGS method. Subsequent validation of non-synonymous missense mutations and non-frameshift indels is planned. Patients signed a multilayered informed consent also covering disclosure or not of different types of incidental findings.
Results:
For each exome, the mean breath of coverage was about 96 % at 10X or more and the mean depth of coverage for targeted region was about 126X. In total, 3570709 SNPs (∼56678 SNPs/sample) and 477801 INDELs (7584 INDELs/sample) were called. Of them, 20829 SNPs (331 SNPs/sample) and 16071 INDELs (255 INDELs/sample) passed quality filter. In total, 445 variants were found in the publicly available cancer genes panel. Twenty-seven stop-gain/loss, frame-shift insertion/deletion and splice site variants were considered for validation with 454 Roch Junior, among which 22 variants in genes ABCC11, AFP, BARD1, BBS10, CD96, CYP1A1, DNAH11, ESCO2, EXO1, FANCI, FLCN, FLT4, HPS6, MYH8, NME8, PALB2, PDE11A, RECQL4, TTC8 were validated as true positive. Some of these genes have been found earlier to be associated with breast cancer and/other cancer types. Functional prioritization of the remaining 416 non-synonymous and non-frameshift insertion/deletions was also done in-silico before further sequencing validation, which is ongoing. The mutations found are further clinically validated by examining other affected and non-affected family members and mining the literature. Some of the mutations in known cancer predisposing genes are considered for prudent application in clinical counseling. Genotype-phenotype correlations are being examined.
Conclusion:
Next-generation sequencing enabled us to detect variants with high/low penetrance in known cancer predisposing genes in > 35% of BRAX families, in addition to many novel variants in many other genes not yet tied to cancer predisposition occurring singly or in combination with known cancer gene mutations. Validated variants are further examined in the families for co-segregation with the disease and potential application in counseling.
Citation Format: Shahi RB, Caljon B, De Brakeleer S, Decoster L, Fontaine C, Vanacker L, Vanhoeij M, Pauwels I, Bonduelle M, Vandooren S, Croes D, Teugels E, De Greve J. Exome based germline mutation detection in a panel of 372 cancer associated genes in BRCA1/2-negative familial breast cancer patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD7-04.
Collapse
Affiliation(s)
- RB Shahi
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - B Caljon
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - S De Brakeleer
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - L Decoster
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - C Fontaine
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - L Vanacker
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - M Vanhoeij
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - I Pauwels
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - M Bonduelle
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - S Vandooren
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - D Croes
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - E Teugels
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - J De Greve
- Laboratory of Medical and Molecular Oncology and Familial Cancer Clinic, Oncologisch Centrum and BRIGHTcore, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|